| Abstract |
Objective: To investigate the efficacy and prognosis of butylphthalide regimen in patients with Parkinsons disease and depression. Methods: 60 patients with Parkinsons disease and depression were selected and treated in our hospital from February 2017 to February 2019. The patients were divided into two groups by random number table extraction method. The total effective rate of routine treatment (control group, n=30) and butylphthalide administration (observation group, n=30) were compared. The recovery of symptoms, depressive symptoms and hematological indicators were compared. Results: The total effective rate of Parkinsons and depression patients in the observation group was 96.67% and 76.67% in the control group, the difference was statistically significant (P < 0.05). Before treatment, there was no difference in UPDRS score between the two groups (P > 0.05). After treatment, the measured values of each group decreased, and the degree of reduction in the observation group was more significant than that in the control group, with statistical significance (P < 0.05). Before treatment, there was no difference in the self-rating depression scale (HAMD) score between the two groups (P > 0.05). After treatment, the measured values of each group decreased, and the degree of reduction in the observation group was more significant than that in the control group, with statistical significance (P < 0.05). Before treatment, there was no difference in the hematological indexes of recombinant human Parkinson protein 7 (PARK7), neurotrophic factor 3 (NT-3), and C-reactive protein (CRP) between the two groups (P > 005). After treatment, both PAPK7 and CRP decreased and NT-3 increased, and the degree of decrease and increase in the observation group was more significant than that in the control group, the difference was statistically significant. Significance (P < 0.05). CONCLUSION: Butylphthalide regimen can enhance the clinical effect, improve Parkinsons and depressive symptoms, protect nerve cells and promote the recovery of nerve function in patients with Parkinsons disease and depression.
|